Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

PHASE2UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 13, 2017

Primary Completion Date

June 1, 2019

Study Completion Date

June 1, 2022

Conditions
Relapsed and/or Refractory Multiple Myeloma
Interventions
DRUG

Carfilzomib, Thalidomide and Dexamethasone

"Carfilzomib will be given on days 1,2,8,9,15,16 in a 4-week (28 day) cycle during induction cycles 1-12, followed by days 1,2,15,16 in a 4-week cycle during maintenance cycles 13-18 (section 4.0) Dexamethasone, 40mg po will be given on days 1,8,15, 22 in a 4-week cycle during induction cycles 1-12, followed by days 1,15, in a 4-week cycle during maintenance cycles 13-18.~Thalidomide, 100mg po will be given daily during induction cycles 1-12 only."

Trial Locations (4)

Unknown

NOT_YET_RECRUITING

Queen Mary Hospital, Hong Kong

RECRUITING

National University Hospital, Singapore

NOT_YET_RECRUITING

South Korea

NOT_YET_RECRUITING

National Taiwan University, Taipei

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

The Australasian Leukaemia & Lymphoma Group (ALLG)

UNKNOWN

collaborator

International Myeloma Foundation

OTHER

collaborator

Celgene

INDUSTRY

lead

National University Hospital, Singapore

OTHER